Gold price jumps on Venezuela strikes, lifting GLD and gold miners in New York trade
5 January 2026
1 min read

Gold price jumps on Venezuela strikes, lifting GLD and gold miners in New York trade

New York, January 5, 2026, 13:31 EST — Regular session

  • Spot gold climbed to a one-week high after U.S. strikes in Venezuela revived safe-haven demand.
  • The SPDR Gold Shares ETF (GLD) and the VanEck Gold Miners ETF (GDX) rose, with miners outperforming bullion-linked funds.

Shares of SPDR Gold Shares (GLD), a gold-backed exchange-traded fund, rose on Monday as bullion prices jumped on renewed geopolitical risk tied to Venezuela.

The move matters because gold entered 2026 near record levels after a strong 2025 run, leaving markets sensitive to shocks that can trigger rapid shifts in positioning.

It also lands as investors reassess the outlook for U.S. interest rates, a key driver for gold because the metal does not pay interest and tends to look more attractive when yields fall.

Spot gold rose 2.7% to $4,447.05 an ounce by 11:20 a.m. ET, after earlier touching its highest level since Dec. 29, according to Reuters. “The situation around Venezuela has clearly reactivated safe-haven demand,” said Alexander Zumpfe, a precious metals trader at Heraeus Metals Germany. 1

GLD was up 2.6% at $408.82 in early afternoon New York trading, while the VanEck Gold Miners ETF (GDX) gained 4.6%. Newmont climbed 2.4% and Agnico Eagle rose 4.5%, tracking the jump in gold prices.

Gold is often described as a “safe haven” because investors tend to buy it when the risk of a broader market drawdown rises. Miners can move more than bullion-linked funds because their profits are leveraged to the metal price once costs are covered.

Still, traders flagged uncertainty around how long the bid for gold can last if geopolitical risk cools. A stronger run of U.S. data that pushes Treasury yields higher could also sap demand for a non-yielding asset like gold.

Investors’ next focus is Friday’s U.S. Employment Situation report for December 2025, scheduled for 8:30 a.m. ET, for clues on the path of Federal Reserve policy. 2

Stock Market Today

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

7 February 2026
XRP fell about 5% Saturday to $1.42, extending a 22% weekly drop as thin liquidity and macro jitters drove sharp swings. Bitcoin rebounded above $70,000 after a brief plunge, while ether surged 12%. Ripple outlined plans for an “Institutional DeFi” roadmap, including a new lending protocol and permissioned DEX. The Federal Reserve held rates steady last week, with officials signaling caution on inflation.
Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next
Previous Story

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Silver price stock SLV climbs nearly 6% as Venezuela strikes lift safe-haven demand
Next Story

Silver price stock SLV climbs nearly 6% as Venezuela strikes lift safe-haven demand

Go toTop